GlassScriptPhysician profile
Stephanie Goldpin
NPI 1306815857
$5,668.43
in general payments reported to CMS, 2019-2025
33 companies · $997 in 2025
The $997 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $865 · 2020: $686 · 2021: $544 · 2022: $847 · 2023: $1,033 · 2024: $696 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,726.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,086.05 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $718.65 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $594.98 | 2023-2025 | Gemtesa, Myfembree |
| Astellas Pharma US INC | $567.83 | 2019-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $312.10 | 2019-2025 | |
| Therapeuticsmd, INC. | $291.00 | 2019-2022 | |
| Exact Sciences Corporation | $269.46 | 2023-2025 | Cologuard Collection Kit |
| Avion Pharmaceuticals | $216.88 | 2019-2022 | |
| Pfizer INC. | $210.91 | 2019-2024 | |
| Biogen, INC. | $142.33 | 2024-2025 | Zurzuvae |
| Aspira Women'S Health INC | $136.32 | 2024-2025 | Ova1 |
| Evofem Biosciences, INC. | $130.11 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $123.89 | 2019-2023 | Gardasil 9 |
| Duchesnay USA Incorporated | $102.99 | 2019 | |
| Myovant Sciences INC. | $101.44 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $95.94 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Millicent US INC | $93.22 | 2025 | Intrarosa, Femlyv |
| Exeltis, USA INC. | $81.97 | 2019-2020 | |
| Agile Therapeutics, INC. | $54.18 | 2021-2022 | |
| Mission Pharmacal Company | $53.64 | 2019-2020 | |
| Urovant Sciences INC | $43.67 | 2022 | |
| Vertical Pharmaceuticals, LLC | $39.66 | 2019 | |
| Allergan, INC. | $33.08 | 2019 | |
| Scynexis, INC. | $26.96 | 2022 | |
| Sanara Medtech INC. | $21.27 | 2021 | |
| Lupin INC. | $19.56 | 2019 | |
| Innovation Technologies INC | $17.12 | 2025 | Irrisept |
| Organon LLC | $16.59 | 2022 | |
| Daiichi Sankyo INC. | $15.23 | 2019 | |
| Mallinckrodt Enterprises LLC | $13.72 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.26 | 2019 | |
| Olympus America INC. | $12.99 | 2019 | |
| Ferring Pharmaceuticals INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Goldpin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.